Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function

Abstract

Endothelial progenitor cells maintain endothelium integrity by replacing injured endothelial cells. Cholesterol-lowering promotes either endothelial progenitor cells mobilization or improves endothelial function. It is unknown whether improving endothelial function with statin is associated with a parallel increased endothelial progenitor cells availability. Thirty-two hypercholesterolemic patients were assigned to 4-week rosuvastatin (10 mg daily) and 16 hypercholesterolemic served as controls. Circulating endothelial progenitor cells, brachial artery flow-mediated vasodilatation, an index of endothelial function, and the lipid profile were measured before and after the 4-week statin therapy. At baseline, we found a correlation between circulating endothelial progenitor cells and flow-mediated vasodilatation (r = .31, P = .029). At the end of the 4-week intervention with rosuvastatin there was a 37% reduction in low-density lipoprotein cholesterol (P < .001) and a significant 72% increase in the number of endothelial progenitor cells and flow-mediated vasodilatation (4.7 + 0.7% to 8.8 + 0.4%, P < .001). Endothelial progenitor cells and flow-mediated vasodilatation were unchanged at the end of the study in patients not taking statin. A correlation emerged between endothelial progenitor cells and flow-mediated vasodilatation variations (r = .52, P < .001), this correlation being still significant after controlling for blood cholesterol reduction. In conclusion, short-term rosuvastatin therapy contributes in hyperchoelsterolemic patients to improving endothelial function by lowering cholesterol and increasing the number of circulating endothelial progenitor cells; the latter effect appears to be partly independent from reduction in plasma cholesterol.

Keywords

hypercholesterolemia endothelial progenitor cells endothelial dysfunction statin

References

Chen CH , Jiang T. , Yang JH , et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003;107: 2102-2108.

Maas R. , Schwedhelm E. , Kahl L. , et al. Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem . 2008;54:292-300.

Lupattelli G. , Marchesi S. , Roscini AR , et al. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. Am J Cardiol. 2002;90:648-650.

Xu Q. The impact of progenitor cells in atherosclerosis. Nat Clin Pract Cardiovasc Med. 2006;3:94-101.

Mannarino E. , Pirro M. Endothelial injury and repair: a novel theory for atherosclerosis. Angiology. 2008;59: 69S-72S.

Pirro M. , Schillaci G. , Bagaglia F. , et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis . 2008;197: 757-767.

Hill JM , Zalos G. , Halcox JP , et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003 ;348:593-600.

Chen JZ , Zhang FR , Tao QM , Wang XX , Zhu JH , Zhu JH Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin Sci (Lond) . 2004;107:273-280.

Pirro M. , Schillaci G. , Paltriccia R. , et al. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:2530-2535.

10.

Mohler ER 3rd , Fang Y. , Shaffer RG , et al. Hypercholesterolemia suppresses Kir channels in porcine bone marrow progenitor cells in vivo. Biochem Biophys Res Commun. 2007;358:317-324.

11.

Wassmann S. , Werner N. , Czech T. , Nickenig G. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res. 2006;99: e74-e83.

12.

Op den Buijs J. , Musters M. , Verrips T. , Post JA , Braam B. , van Riel N. Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening. Am J Physiol Heart Circ Physiol . 2004;287: H2651-H2658.

13.

Chu K. , Jung KH , Lee ST , et al. Circulating endothelial progenitor cells as a new marker of endothelial dysfunction or repair in acute stroke. Stroke . 2008;39: 1441-1447.

14.

Marchesi S. , Lupattelli G. , Siepi D. , et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000;36:617-621.

15.

Martínez-González J. , Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des. 2007 ;13:1771-1786.

16.

Tsiara S. , Elisaf M. , Mikhailidis DP Early vascular benefits of statin therapy. Curr Med Res Opin . 2003;19: 540-556.

17.

Vasa M. , Fichtlscherer S. , Adler K. , et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.

18.

Deschaseaux F. , Selmani Z. , Falcoz PE , et al. Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors. Eur J Pharmacol. 2007;562:111-118.

19.

Kusuyama T. , Omura T. , Nishiya D. , et al. The effects of HMG-CoA reductase inhibitor on vascular progenitor cells. J Pharmacol Sci. 2006;101:344-349.

20.

Jones PH , Davidson MH , Stein EA , et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.

21.

Thum T. , Tsikas D. , Stein S. , et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol. 2005;46: 1693-1701.

22.

Gerli R. , Schillaci G. , Giordano A. , et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109: 2744-2748.

23.

Vaudo G. , Marchesi S. , Gerli R. , et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004 ;63: 31-35.

24.

Llevadot J. , Murasawa S. , Kureishi Y. , et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest . 2001;108: 399-405.

25.

Assmus B. , Urbich C. , Aicher A. , et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92:1049-1055.

26.

Croce G. , Passacquale G. , Necozione S. , Ferri C. , Desideri G. Nonpharmacological treatment of hypercholesterolemia increases circulating endothelial progenitor cell population in adults. Arterioscler Thromb Vasc Biol. 2006;26:e38-e39.

27.

Werner N. , Priller J. , Laufs U. , et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22:1567-1572.